Antibody engineering in practice: choosing between antibody formats before a sequence, what an scfv antibody or another antibody fragment gains and loses against a full recombinant antibody, what an antibody fab, a fab antibody, a fab fragment antibody, a fab fragment of antibody, a fab of antibody or a bare fab fragment keeps, how a human igg1 antibody framework is chosen, why recombinant antibodies and recombinant monoclonal antibodies or a recombinant monoclonal antibody end lot variation, how recombinant antibody expression and recombinant antibody production are staged, what an antibody developability assessment screens for, and where a trispecific antibody and trispecific antibodies stop being manufacturable

The decisions, in order

1. Choose the format from the job, not from the platform. A full immunoglobulin gives long circulating half-life and effector function. A Fab removes effector function and keeps bivalency out of the picture. An scfv antibody is small, penetrates tissue well, is easy to display and express, and is cleared quickly and prone to aggregation. For a research reagent, an scFv is often ideal; for a therapeutic, rarely as the final format.
2. Fix the sequence and make it recombinant early. Recombinant monoclonal antibodies are expressed from a known sequence, so the reagent is identical indefinitely and can be reformatted at will. The hybridoma that produced the original clone will eventually drift or be lost, which is why sequencing it is worth doing while it is healthy.
3. Humanise only as far as the application requires. A research reagent does not need humanising. A therapeutic candidate does, and grafting the complementarity determining regions onto a human framework usually costs affinity that then has to be recovered by back-mutating framework residues one at a time.
4. Affinity mature against the real requirement. Higher affinity is not always better: for a tissue-penetrating agent very high affinity can trap the molecule at the periphery of a target. Define the affinity you need from the application before running the campaign.
5. Screen developability before committing. Thermal stability, aggregation propensity, expression titre, polyreactivity and the presence of chemical liabilities in the sequence can all be assessed on small quantities. A candidate that fails these at milligram scale will fail them at kilogram scale for much more money.

Display platforms and what they bias towards

Phage display is cheap, fast and biased towards sequences that express well in bacteria. Yeast display supports quantitative sorting on affinity and handles some formats bacteria cannot. Mammalian display is closest to the final production context and is the most expensive.

Every platform selects for expressibility in its own host as well as for binding. Running a counter-screen in the intended production system before committing to a lead catches the candidates that only work where they were found.

Sequence liabilities worth removing early

Unpaired cysteines, deamidation motifs in a binding loop, oxidation-prone methionines and glycosylation sites in the variable region are all identifiable from the sequence and all cause heterogeneity later. Removing them costs a round of mutagenesis now and a manufacturing investigation later.

Test each removal for effect on binding. A liability sitting inside a contact residue cannot simply be deleted, and that is worth knowing before the campaign is planned around it.

Intellectual property and freedom to operate

Formats, linkers, framework sequences and engineering methods are all patented territory. A format chosen for technical reasons can carry a licensing requirement that changes the economics of the programme.

Ask any engineering provider what they license and what they own before work starts. Ownership of the resulting sequence, of improvements and of the right to produce elsewhere are separate terms and providers differ widely.

Common questions

What is an scfv antibody?

A single chain variable fragment: the heavy and light variable domains joined by a peptide linker into one polypeptide. It keeps the binding site, loses the constant regions, and is small, easy to express and easy to display.

Why convert a hybridoma to a recombinant antibody?

Permanence and control. Once the variable region sequence is known the reagent can be produced indefinitely, reformatted into any isotype or fragment, and produced without lot-to-lot variation.

Do recombinant monoclonal antibodies still need validation?

Yes. A defined sequence guarantees consistency, not correctness. A recombinant reagent that cross-reacts will cross-react identically forever, which is a reproducible error rather than an absent one.

When should developability screening happen?

As soon as there is a panel worth ranking, which is usually well before lead selection. Screens done after a lead is chosen tend to be used to justify it rather than to choose it.

Browse by service class

• Compare Gene synthesis on advertised prices